文献速递瘢痕与激光创面修复

程序性细胞死亡基因与增生性瘢痕的因果关联:多组学孟德尔随机化与初步实验验证

Causal links between programmed cell death and hypertrophic scars: Integrative analysis of multi-omics Mendelian randomization and preliminary experimental validation.
PubMed 文献 · Burns · 2025-08-19

本研究利用多组学孟德尔随机化分析,探讨程序性细胞死亡基因与增生性瘢痕的因果关系,并初步实验验证。结果发现GLB1在DNA甲基化、基因表达和蛋白丰度层面均与增生性瘢痕风险因果相关,并筛选出Fulvestrant等候选药物。

要点

  • GLB1在三个组学层面均与增生性瘢痕风险因果相关。
  • 共鉴定出1个一级基因、12个二级基因和2个三级基因。
  • Fulvestrant在增生性瘢痕组织和成纤维细胞中显示抑制效果。

核心结论

  • 程序性细胞死亡基因与增生性瘢痕形成存在因果关联,GLB1是核心基因。
  • Fulvestrant可能通过调节纤维化相关通路治疗增生性瘢痕。

研究设计与样本

  • 利用eQTL Gen、UKB-PPP和FinnGen数据库的QTL数据,进行多组学孟德尔随机化分析。
  • 采用IVW、FDR、Cochran's Q、I²、MR-Egger、MR-PRESSO、留一法、共定位和Steiger过滤等方法。
  • 对一级基因进行药物预测和分子对接,并在组织和细胞水平验证。

主要发现

  • GLB1(cg05120113)在DNA甲基化层面与HS风险相关(OR=1.0972, 95%CI:1.0532-1.1430, FDR=0.0163)。
  • GLB1在基因表达层面与HS风险相关(OR=1.2923, 95%CI:1.1816-1.4135, FDR<0.001)。
  • GLB1在蛋白丰度层面与HS风险相关(OR=1.5430, 95%CI:1.3296-1.7905, FDR<0.001)。
  • 候选药物Fulvestrant(adjusted P=0.046, Affinity=-8.8 kcal/mol)和Cyperquat(adjusted P=0.036, Affinity=-6.2 kcal/mol)。
  • 在HS组织和HSFs中验证了GLB1表达及Fulvestrant的抑制作用,并观察到TGF-β1和α-SMA的mRNA和蛋白表达变化。

关键数值与推荐

  • 鉴定出1个一级基因(GLB1)、12个二级基因(DAPK2, AP4E1, ARSA, CTSF, MSH6, NEDD4, PDK1, PELI3, RB1, UNC13D, CTSC, GZMB)和2个三级基因(NOS3, ITGA6)。

临床怎么用

  • GLB1可作为增生性瘢痕的潜在治疗靶点。
  • Fulvestrant可能作为增生性瘢痕的治疗药物,但需进一步临床验证。

局限性

  • 研究主要基于公共数据库和初步实验验证,需要更多体内外实验和临床研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to explore the causal relationship between programmed cell death (PCD) genes and the formation of hypertrophic scars (HS) using integrative multi-omics analysis (including DNA methylation, gene expression, and protein abundance) alongside preliminary experimental validation. METHODS: We leveraged publicly available databases (eQTL Gen, UKB-PPP, and FinnGen) to obtain quantitative trait loci (QTLs) data of DNA methylation, gene expression and protein abundance. We employed Mendelian randomization (MR) approaches to uncover causal relationships and validate robustness. The methods used included inverse variance weighted (IVW) analysis, false discovery rate (FDR), Cochran's Q test, I² statistic, MR-Egger regression, MR-PRESSO, leave-one-out method, co-localization analysis, and Steiger filtering test. Then, the multi-omic MR results were integrated and three tiers of genes were identified. Further, the tier 1 genes were chosen to perform drug prediction in DSigDB and molecular docking analyses with Autodock Vina. Lastly, the effects of the selected genes and drugs in HS were validated at both the tissue and cellular levels. RESULTS: Through integrating multi-omics data, we identified one tier 1 gene (GLB1), twelve tier 2 genes (including DAPK2, AP4E1, ARSA, CTSF, MSH6, NEDD4, PDK1, PELI3, RB1, UNC13D, CTSC, and GZMB), and two tier 3 genes (NOS3 and ITGA6), all of which show varying associations with HS. Particularly, the GLB1(cg05120113) was causal associated with HS risk in DNA methylation (OR=1.0972, 95 % CI: 1.0532-1.1430, FDR=0.0163), gene expression (OR=1.2923, 95 % CI: 1.1816-1.4135, FDR<0.001) and protein abundance (OR=1.5430, 95 % CI: 1.3296-1.7905, FDR<0.001). The candidate drugs for GLB1 included Fulvestrant (adjusted P = 0.046, Affinity=-8.8 kcal/mol) and Cyperquat (adjusted P = 0.036, Affinity=-6.2 kcal/mol). Further, the GLB1 expression and inhibitory effect of Fulvestrant were validated in HS tissues and HSFs. Additionally, significant changes in the mRNA and protein expression levels of fibrosis-related markers, including TGF-β1 and α-SMA, were observed in HSFs. FINDINGS: This study provides robust evidence for the causal involvement of PCD genes in HS formation and identified GLB1 along with 14 other potential genes. Fulvestrant demonstrated therapeutic potential for HS by modulating fibrosis-related pathways in fibroblasts.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhao C, Zhao R, et al. Causal links between programmed cell death and hypertrophic scars: Integrative analysis of multi-omics Mendelian randomization and preliminary experimental validation. Burns. 2025. PMID: 40865488. doi:10.1016/j.burns.2025.107667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。